Suppliers / Lotus Pharmaceutical Co Ltd Nantou Plant
Lotus Pharmaceutical Co Ltd Nantou Plant
Taiwan Updated 9 July 2026
Lotus Pharmaceutical Co Ltd Nantou Plant is a finished-dose manufacturer based in Taiwan. It appears in 71 regulatory filings across 7 regulators, without an active US DMF or CEP on file. Its filings concentrate with NPRA (MY), ARCSA (EC) and MINSA (CR). Its GMP standing is certified by EAEU_EEC and US FDA. Its most recent recorded inspection, by US FDA, closed on 12 April 2024 as VAI.
1
registered plants
1 with an FDA FEI number
71
filings
across 7 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
6 of 6 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.
Inspection history
- 12 April 2024 VAI US FDA
- 31 May 2019 NAI US FDA
- 22 September 2017 VAI US FDA
- 4 June 2015 VAI US FDA
- 16 August 2012 NAI US FDA
- 11 February 2010 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Taiwan, Taiwan | 3005999589 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| NPRA (MY) | 26 | None |
| ARCSA (EC) | 15 | None |
| MINSA (CR) | 15 | None |
| INVIMA (CO) | 6 | None |
| DIGEMAPS (DO) | 4 | None |
| NCELS (KZ) | 4 | None |
| EAEU_EEC | None | 1 |
| US FDA | None | 1 |
Comparing suppliers?
Choose your molecules and target markets. Lotus Pharmaceutical Co Ltd Nantou Plant comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 12 April 2024.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates